Table 1.

Patient characteristics, survival data, and treatment information

No.	Gender	Location	WHO grade	Age at operation (years)	EFS (years)	Event	OS (years)	Outcome	Subgroup	Postoperative treatment
1	M	3rd ventricle	III	12.80	7.43	Second tumor	7.62	Dead	RELA-like	HIT-2000
2	F	Hemispheric	III	4.24	11.68	Censored	11.68	Alive	RELA-like	HIT-2000
3	F	Hemispheric	III	1.90	7.68	Censored	7.68	Alive	RELA-like	HIT-2000
4	F	Pineal region	III	7.18	8.53	Censored	8.53	Alive	RELA-like	HIT-2000
5	M	Hemispheric	III	17.30	7.23	Censored	7.23	Alive	RELA-like	HIT-2000/E-HIT 2004
6	M	Lateral ventricle	III	0.52	4.90	Relapse	5.60	Dead	RELA-like	VEC-Chemotherapy; UKCCSG/SIOP
7	F	Lateral ventricle	III	4.20	5.49	Censored	5.49	Alive	RELA-like	HIT-2000
8	M	Hemispheric	III	6.55	7.48	Censored	7.48	Alive	RELA-like	HIT-2000
9	M	Hemispheric	III	2.32	n.a.	n.a.	n.a.	n.a.	RELA-like	n.a.
10	M	3rd ventricle	II	15.00	10.40	Censored	10.40	Alive	Tanycytic	HIT-2000
11	F	Hemispheric	III	13.64	5.58	Censored	5.58	Alive	Tanycytic	I-HIT-MED
12	M	Hemispheric	II	14.90	3.38	Censored	3.38	Alive	Tanycytic	I-HIT-MED
13	F	Hemispheric	II	6.90	n.a.	n.a.	n.a.	n.a.	Tanycytic	n.a.
14	M	Hemispheric	II	17.80	2.80	Censored	2.80	Alive	Tanycytic	Irradiation only
15a	F	Pineal region	II	10.30	6.90	Censored	6.90	Alive	Tanycytic	Irradiation only
16	F	Hemispheric	III	13.50	6.78	Censored	6.78	Alive	Astroblastoma-like	HIT-2000
17	F	Hemispheric	III	5.25	8.61	Censored	8.61	Alive	Astroblastoma-like	HIT-2000
18b	M	3rd ventricle	III	9.38	1.70	Censored	1.70	Alive	Other	I-HIT-MED

NF2 neurofibromatosis type 2; VEC vincristine, etoposide, cyclophosphamide; PFB posterior fossa ependymoma, group B

^aNF2 patient

^bGenetically classified as PFB ependymoma